Current treatment options for HER2-positive breast cancer patients with brain metastases
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current treatment options for HER2-positive breast cancer patients with brain metastases
Authors
Keywords
Brain metastases, HER2-positive breast cancer, Trastuzumab, Trastuzumab-emtansine, Lapatinib, Neratinib, Tucatinib, Trastuzumab deruxtecan
Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 161, Issue -, Pages 103329
Publisher
Elsevier BV
Online
2021-04-21
DOI
10.1016/j.critrevonc.2021.103329
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Current approaches to the management of brain metastases
- (2020) John H. Suh et al. Nature Reviews Clinical Oncology
- Subtype switching in breast cancer brain metastases: a multicenter analysis
- (2020) Alexander F C Hulsbergen et al. NEURO-ONCOLOGY
- Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
- (2020) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
- (2019) Rachel A. Freedman et al. JOURNAL OF CLINICAL ONCOLOGY
- The HERBA study: a retrospective multi-institutional Italian study on patients with brain metastases from HER2-positive breast cancer
- (2019) Stefania Gori et al. Clinical Breast Cancer
- The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid
- (2019) Agnieszka Karbownik et al. INVESTIGATIONAL NEW DRUGS
- T-DM1 and brain metastases: clinical outcome in HER2-positive metastatic breast cancer
- (2018) Alessandra Fabi et al. BREAST
- Changing Natural History of HER2–Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies
- (2018) Louisa A. Mounsey et al. Clinical Breast Cancer
- Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer
- (2018) Virginia F. Borges et al. JAMA Oncology
- A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
- (2018) Teresa Gamucci et al. CANCER BIOLOGY & THERAPY
- Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes
- (2018) Ece Esin et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases
- (2018) Inbal Zafir-Lavie et al. JOURNAL OF CONTROLLED RELEASE
- Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy
- (2017) Ander Urruticoechea et al. JOURNAL OF CLINICAL ONCOLOGY
- Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial
- (2017) Paul D Brown et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- (2017) Ian E Krop et al. LANCET ONCOLOGY
- A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
- (2017) Patrizia Vici et al. Oncotarget
- Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer
- (2017) Tori B. Terrell-Hall et al. Oncotarget
- Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
- (2016) William Jacot et al. BREAST CANCER RESEARCH AND TREATMENT
- Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
- (2016) Rachel A. Freedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells
- (2016) Tosol Yu et al. Oncotarget
- Activity of T-DM1 in Her2-positive breast cancer brain metastases
- (2015) Rupert Bartsch et al. CLINICAL & EXPERIMENTAL METASTASIS
- Phase 3 Trials of Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for 1 to 4 Brain Metastases: Individual Patient Data Meta-Analysis
- (2015) Arjun Sahgal et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2015) Xavier Pivot et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis
- (2015) Qian Zhang et al. Breast Cancer
- Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
- (2015) Alexandra Canonici et al. Oncotarget
- Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
- (2014) S. M. Swain et al. ANNALS OF ONCOLOGY
- Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases
- (2014) S. Gori et al. ANNALS OF ONCOLOGY
- Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
- (2014) I. E. Krop et al. ANNALS OF ONCOLOGY
- Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2014) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study
- (2014) Masaaki Yamamoto et al. LANCET ONCOLOGY
- Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study
- (2014) Aki Morikawa et al. NEURO-ONCOLOGY
- Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era
- (2013) Erin M. Olson et al. BREAST
- A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
- (2013) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
- (2012) Thomas Bachelot et al. LANCET ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death
- (2011) Romuald Le Scodan et al. BMC CANCER
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
- (2011) A. M. Brufsky et al. CLINICAL CANCER RESEARCH
- Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
- (2011) Nancy U. Lin et al. JOURNAL OF NEURO-ONCOLOGY
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer
- (2011) Kunal S. Taskar et al. PHARMACEUTICAL RESEARCH
- Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
- (2010) G. Metro et al. ANNALS OF ONCOLOGY
- Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
- (2010) S Sutherland et al. BRITISH JOURNAL OF CANCER
- Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer
- (2010) Antonino Musolino et al. CANCER
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic Behavior of Breast Cancer Subtypes
- (2010) Hagen Kennecke et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients WithHER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
- (2010) Vicente Valero et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
- (2010) Martin Kocher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study
- (2010) Michael Andersson et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
- (2010) D. Cameron et al. ONCOLOGIST
- Trastuzumab treatment in patients with breast cancer and metastatic CNS disease
- (2009) T. Pienkowski et al. ANNALS OF ONCOLOGY
- Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases
- (2009) Brian Leyland-Jones JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer
- (2008) I. H. Park et al. ANNALS OF ONCOLOGY
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2008) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More